Pharmacology of Aminophylline for Acute Kidney Injury in Neonates (PAANS)

Stanford University

Status: Terminated

Conditions: Acute Kidney Injury

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT02276170

29957

Details and patient eligibility

About

Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.

Enrollment: 9 patients

Sex: All

Ages: Under 3 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neonate < 3 months post natal age
• Diagnosed with acute kidney injury (AKI)
• Receiving aminophylline for AKI treatment as per local standard of care.

Exclusion criteria

• Presence of anatomical renal anomaly based on postnatal evaluation of the patient (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic kidney, or obstructive uropathy)
• Patient on renal replacement therapy
• Major genetic abnormalities (trisomy 13, 18 or 21).

Trial design

9 participants in 1 patient group

Aminophylline per standard of care